Lyophilized formulations for factor xa antidote

Abstract

The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.

1 . A lyophilized composition prepared by lyophilizing an aqueous solution comprising from 40 mM to 50 mM arginine, from 1% to 3% sucrose (w/v), from 2% to 8% mannitol (w/v) and 5 to 50 mg/mL of a two-chain polypeptide comprising a first chain comprising the amino acid sequence of SEQ ID NO. 4, a second chain comprising the amino acid sequence of SEQ ID NO. 5, and a disulfide bond between a first Cysteine residue at position 98 (Cys98) of SEQ ID NO. 4 and a second Cysteine residue at position 108 (Cys108) of SEQ ID NO. 5, wherein the aqueous solution has a pH from 7.7 to 7.9. 
     
     
         2 . The lyophilized formulation of  claim 1 , wherein the aqueous solution comprises from 40 mM to 50 mM arginine, from 1.5% to 2.5% sucrose (w/v), from 4.5% to 5.5% mannitol (w/v) and at least 10 mg/mL of the polypeptide. 
     
     
         3 . The lyophilized formulation of  claim 2 , wherein the aqueous solution comprises at least 18 mg/mL of the polypeptide. 
     
     
         4 . The lyophilized formulation of  claim 1 , wherein the polypeptide comprises at least an intra-chain disulfide bond for each of the first and second chains. 
     
     
         5 . The lyophilized formulation of  claim 1 , wherein the aqueous solution comprises about 45 mM arginine, about 2% sucrose (w/v), about 5% mannitol (w/v) and about 10 mg/mL of the two-chain polypeptide, wherein the aqueous solution has a pH of about 7.8. 
     
     
         6 . The lyophilized formulation of  claim 1 , wherein the aqueous solution comprises about 45 mM arginine, about 2% sucrose (w/v), about 5% mannitol (w/v) and about 20 mg/mL of the two-chain polypeptide, wherein the aqueous solution has a pH of about 7.8. 
     
     
         7 . The lyophilized formulation of  claim 1 , which comprises L-arginine HCl:sucrose:mannitol in a weight ratio of the range of (0.5-1.4):(1-3):(2-8). 
     
     
         8 . The lyophilized formulation of  claim 1 , which comprises L-arginine HCl:sucrose:mannitol in a weight ratio of the range of (0.9-1):(1.5-2.5):(4.5-5.5). 
     
     
         9 . The lyophilized formulation of  claim 1 , which comprises L-arginine HCl:sucrose:mannitol in a weight ratio of about 0.95:2:5. 
     
     
         10 . An aqueous solution comprising from 40 mM to 50 mM arginine, from 1% to 3% sucrose (w/v), from 2% to 8% mannitol (w/v) and 5 to 50 mg/mL of a two-chain polypeptide comprising a first chain comprising the amino acid sequence of SEQ ID NO. 4, a second chain comprising the amino acid sequence of SEQ ID NO. 5, and a disulfide bond between a first Cysteine residue at position 98 (Cys98) of SEQ ID NO. 4 and a second Cysteine residue at position 108 (Cys108) of SEQ ID NO. 5, wherein the aqueous solution has a pH from 7.7 to 7.9. 
     
     
         11 . An aqueous solution prepared by dissolving the lyophilized formulation of  claim 1  in water.